ensifentrine
ensifentrine: developed by 1 company · 3 clinical trials tracked.
ensifentrine evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could ensifentrine → VRNA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (4)
| Company | Phase |
|---|---|
| Verona Pharma plc (VRNA) Chronic Obstructive Pulmonary Disease; COPD | Phase 3 |
| Verona Pharma plc (VRNA) Chronic Obstructive Pulmonary Disease; COPD | Phase 3 |
| Verona Pharma plc (VRNA) Chronic Obstructive Pulmonary Disease; COPD | Phase 3 |
| Verona Pharma plc (VRNA) Maintenance treatment of chronic obstructive pulmonary disea… | Approved |
Clinical Trials (3)
A Phase II, Randomized, Double-Blind, Cross-Over Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-Glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Primary endpoint: Ensifentrine single dose area under the curve from time 0 to time t (AUC0-t)
A Phase IIb, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ensifentrine-glycopyrrolate Fixed-dose Combination at Two Dose Levels Compared to Glycopyrrolate or Ensifentrine Monotherapy in Subjects With COPD
Primary endpoint: Change from baseline in average forced expiry volume in 1 second (FEV1) area under the curve versus time, from time 0 to 4 hours (AUC0-4h)
A Randomized, Double-Blind, Placebo-Controlled, Two-period Cross-over Study of the Effect of Ensifentrine on Sputum Markers of Inflammation in Patients With COPD
Primary endpoint: The change from baseline in sputum neutrophils at Week 8 (absolute change in cell numbers)
Frequently asked questions
Who is developing ensifentrine?
ensifentrine is being developed by Verona Pharma plc.
How many clinical trials involve ensifentrine?
BioSniper tracks 3 clinical trials involving ensifentrine.